Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Mar 29

PMID 36984559

Authors

Yoo-Ri Chung

Kyung Ho Lee

Kihwang Lee

Affiliations

Soon will be listed here.

Abstract

: We investigated and compared the efficacy of three and five monthly loading regimens of an intravitreal aflibercept injection (IVA) in patients with diabetic macular edema (DME). : This was a retrospective study that included patients diagnosed with DME and treated with an either three or five monthly aflibercept loading regimen from July 2018 to March 2022. Information on clinical characteristics and changes in the central retinal thickness (CRT) were obtained from medical records. : In total, 44 eyes of 44 patients with DME treated with IVA were included in this study, with 30 eyes treated with 3-monthly loadings (three-loading group) and 14 eyes with 5-monthly loadings (five-loading group). The mean CRT significantly decreased from the baseline one month after loading in both the three-loading and five-loading groups ( < 0.001). Four cases were refractory to treatment in the three-loading group, while there were no cases of refractory DME in the five-loading group. The stability rate was significantly higher in the five-loading group at three months after loading ( = 0.033). : Five-monthly loading regimens of IVA might be favorable for DME considering the rate of refractory cases, stable duration, and the importance of early responsiveness to IVA in DME.

References

Starr M, Salabati M, Mahmoudzadeh R, Patel L, Ammar M, Hsu J . Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting. Am J Ophthalmol. 2021; 232:90-97. DOI: 10.1016/j.ajo.2021.06.030. View

Dascalu A, Rizzo M, Rizvi A, Pantea Stoian A, Iancu R, Stana D . Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema - A Systematic Review. Curr Pharm Des. 2022; 28(21):1758-1768. DOI: 10.2174/1381612828666220425101030. View

Kocur I, Resnikoff S . Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002; 86(7):716-22. PMC: 1771203. DOI: 10.1136/bjo.86.7.716. View

Avitabile T, Azzolini C, Bandello F, Boscia F, De Falco S, Fornasari D . Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper. Eur J Ophthalmol. 2017; 27(6):627-639. DOI: 10.5301/ejo.5001053. View

Heier J, Korobelnik J, Brown D, Schmidt-Erfurth U, Do D, Midena E . Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016; 123(11):2376-2385. DOI: 10.1016/j.ophtha.2016.07.032. View

Staurenghi G, Sadda S, Chakravarthy U, Spaide R . Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus. Ophthalmology. 2014; 121(8):1572-8. DOI: 10.1016/j.ophtha.2014.02.023. View

Cunha-Vaz J, Coscas G . Diagnosis of macular edema. Ophthalmologica. 2010; 224 Suppl 1:2-7. DOI: 10.1159/000315156. View

Wilkins C, Sobol E, Lema G, Lee J, Rosen R, Deobhakta A . Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy. Eur J Ophthalmol. 2021; 32(5):NP37-NP41. DOI: 10.1177/11206721211004391. View

Korobelnik J, Do D, Schmidt-Erfurth U, Boyer D, Holz F, Heier J . Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121(11):2247-54. DOI: 10.1016/j.ophtha.2014.05.006. View

10.

Stewart M, Browning D, Landers M . Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018; 66(12):1751-1762. PMC: 6256889. DOI: 10.4103/ijo.IJO_1217_18. View

11.

Sorour O, Levine E, Baumal C, Elnahry A, Braun P, Girgis J . Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2022; 68(2):147-174. DOI: 10.1016/j.survophthal.2022.11.008. View

12.

Brownlee M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54(6):1615-25. DOI: 10.2337/diabetes.54.6.1615. View

13.

Wells J, Glassman A, Ayala A, Jampol L, Aiello L, Antoszyk A . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13):1193-203. PMC: 4422053. DOI: 10.1056/NEJMoa1414264. View

14.

Garweg J, Stefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S . Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Adv Ther. 2022; 39(6):2701-2716. PMC: 9123040. DOI: 10.1007/s12325-022-02119-z. View

15.

Virgili G, Parravano M, Evans J, Gordon I, Lucenteforte E . Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017; 6:CD007419. PMC: 6481463. DOI: 10.1002/14651858.CD007419.pub5. View

16.

Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R . Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016; 2016:2156273. PMC: 5059543. DOI: 10.1155/2016/2156273. View

17.

Hirano T, Toriyama Y, Takamura Y, Sugimoto M, Nagaoka T, Sugiura Y . Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial. Jpn J Ophthalmol. 2021; 65(3):354-362. DOI: 10.1007/s10384-021-00820-0. View

18.

Kern C, Schiefelbein J, Fu D, Schworm B, Sim D, Herold T . Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept - A Retrospective Cohort Study. Clin Ophthalmol. 2020; 14:533-541. PMC: 7049742. DOI: 10.2147/OPTH.S237586. View

19.

Salimi A, Vila N, Modabber M, Kapusta M . One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders. Indian J Ophthalmol. 2021; 69(2):360-367. PMC: 7933844. DOI: 10.4103/ijo.IJO_459_20. View

20.

Wells J, Glassman A, Ayala A, Jampol L, Bressler N, Bressler S . Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-9. PMC: 4877252. DOI: 10.1016/j.ophtha.2016.02.022. View